During 15 years period (1992-2007) the researchers of the Institute have reached significant success in bioregulation and gerontology. Active research and practical efforts resulted in the following fundamental achievements:
The concept of peptide regulation of ageing has been developed, basic mechanisms of premature ageing development have been identified. It was found, that the administration of peptide bioregulators resulted in a reliable increase in the mean life span of animals by 30-40%. Geroprotective activity of the peptides is related to their effect on the mechanisms of immunity, hormonal regulation, antioxidant protection, regulation of genes expression and telomerase activity.
A new practical direction in modern medicine – bioregulation therapy – has been developed. Bioregulation therapy is based on pathogenetically substantiated administration of peptide bioregulators. It was found, that the administration of thymus and pineal gland peptides to old and very old patients restores the level of melatonin, as well as the indices of antioxidant protection, immune, endocrine and cardiovascular systems and brain functions, thus leading to a reliable decrease in the death rate.
There has been established a cardioprotective effect of Epithalamin in case of coronary invasions (coronary angiography and coronary angioplastics with coronary arteries stenting) in geriatric patients suffering ischemic heart disease. Administration of Epithalamin to old and very old patients at the acute stage of myocardium infarction entailed a decrease in complication occurrence by 50-70%, as well as a 2-fold fall in the death rate, and reduced periods of staying in the hospital.
In cooperation with the leading Russian specialists in genetics, a completely new system of diagnostics of the structural organization of 20 genes, allowing to identify the predisposition to cardiovascular diseases, tumors, as well as metabolic and regulatory disorders, was designed.
A method of in vivo diagnostics of Alzheimer’s disease, based on verifying the expression of tau-protein in human blood lymphocytes, was developed, which confirms the systemic character of this disease.
There was recognized the role of melatonin in the mechanisms of ageing and carcinogenesis, as well as its value as a biological marker in the diagnostics and prognosis of age-related diseases development.
A new group of geroprotective pharmaceuticals and parapharmaceuticals was introduced into mass production.
The achievements of the Institute are protected by 125 patents, including 40 foreign ones (USA, Japan, Switzerland, Australia etc.), as well as by 70 trademarks.
There has been created a scientific school in the field of “biogerontology” (130 doctorate and Ph.D. theses were prepared and upheld, more than 700 research papers were published, including 48 monographs, 43 scientific publications, guidelines, methodological references, recommendations).